BN80927 in Patients With Advanced Malignant Solid Tumors
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine the maximum tolerated dose and the recommended
dose of BN80927 in patients with advanced malignant solid tumors.